Loss of peroxiredoxin-2 exacerbates eccentric contraction-induced force loss in dystrophin-deficient muscle by Olthoff, John T. et al.
ARTICLE
Loss of peroxiredoxin-2 exacerbates eccentric
contraction-induced force loss in dystrophin-
deficient muscle
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Dawn A. Lowe2 & James M. Ervasti1,4
Force loss in skeletal muscle exposed to eccentric contraction is often attributed to injury.
We show that EDL muscles from dystrophin-deficient mdx mice recover 65% of lost force
within 120min of eccentric contraction and exhibit minimal force loss when the interval
between contractions is increased from 3 to 30min. A proteomic screen of mdx muscle
identified an 80% reduction in the antioxidant peroxiredoxin-2, likely due to proteolytic
degradation following hyperoxidation by NADPH Oxidase 2. Eccentric contraction-induced
force loss in mdx muscle was exacerbated by peroxiredoxin-2 ablation, and improved by
peroxiredoxin-2 overexpression or myoglobin knockout. Finally, overexpression of γcyto- or
βcyto-actin protects mdx muscle from eccentric contraction-induced force loss by blocking
NADPH Oxidase 2 through a mechanism dependent on cysteine 272 unique to cytoplasmic
actins. Our data suggest that eccentric contraction-induced force loss may function as an
adaptive circuit breaker that protects mdx muscle from injurious contractions.
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Duchenne muscular dystrophy (DMD) is an X-linkedrecessive disease caused by deleterious mutations in theDMD gene, rendering non-functional forms or complete
absence of the protein dystrophin1. Dystrophin is normally
enriched at subsarcolemmal structures known as costameres,
where it links the cortical actin cytoskeleton to the extracellular
matrix through interactions with a membrane-bound glycopro-
tein complex2,3. DMD is one of the most common and severe
forms of muscular dystrophy, affecting ~1:4000 boys4. Dystro-
phin deficiency leads to progressive weakness and deterioration of
skeletal muscle beginning at 3 to 5 years of age. DMD patients
typically become non-ambulatory by 12 years of age, with death
ensuing by the second or third decade due to cardiac or
respiratory failure5. Although several treatments exist, including
ventilatory support and use of corticosteroids6,7, there is no cure
for DMD.
Much of the mechanistic understanding of DMD has been
elucidated in the dystrophin-deficient mdx mouse model, which
encodes a nonsense mutation in exon 23 of the DMD gene
ablating dystrophin protein expression8,9. Although the mdx
mouse presents a milder phenotype compared to DMD
patients10, several aspects of the disease are recapitulated in the
model, including pervasive muscle weakness11, substantial his-
topathology due to repetitive rounds of muscle degeneration and
regeneration12, and elevated serum creatine kinase levels13.
Landmark studies by Sweeney and colleagues14 and Moens
et al.15 demonstrated that mdx skeletal muscles are particularly
sensitive to precipitous loss of contractile function after per-
forming eccentric contractions (ECCs). With validation by many
laboratories around the world as a highly robust and reproducible
phenotype of murine dystrophy, the measurement of force loss
induced by ECCs in mdx mice has emerged as an important
quantitative readout for the efficacy of potential DMD thera-
pies16,17. However, the molecular mechanism by which ECC
force loss occurs in mdx muscle is poorly understood.
ECC force loss in mdx muscle is frequently referred to as
contraction-induced “injury” or “damage”, implying that some
form of slowly reversible damage has occurred within the myo-
fiber that would take days to fully recover18. Recent studies
suggest that morphological defects at the neuromuscular junc-
tion19, loss of sarcolemmal excitability20, and myofibrillar dys-
function21 all contribute to ECC force loss in mdx muscle. Several
signaling mechanisms have also been implicated, including cal-
cium22,23, Akt/PKB kinase24, neuronal nitric oxide synthase25,
and redox pathways26. The effect of reactive oxygen species
(ROS) on ECC force loss is particularly interesting considering
recent discoveries of aberrant stretch-activated ROS in mdx
skeletal muscle27–30.
In this study, we demonstrate that isolated mdx skeletal muscle
recovers 65% of lost force production within 120 min of ECC and
loses minimal force if the interval between eccentric contractions
is increased from 3 to 30 min. To gain a mechanistic under-
standing of ECC force loss, we employed isobaric tags for relative
and absolute quantification (iTRAQ) proteomics to identify
proteins that were differentially expressed in skeletal muscle of
mdx mice overexpressing nonmuscle γcyto-actin (mdx/Actg1-TG),
which we have previously shown are significantly protected
against ECC force loss31. We identified the antioxidant enzyme
peroxiredoxin-2 (PrxII) as significantly decreased in mdx muscle
compared to wild type (WT), but restored to WT levels in mdx/
Actg1-TG mice. We verify that hyperactive NADPH oxidase 2
(NOX2)-dependent ROS production contributes to ECC force
loss and likely causes proteolytic degradation of hyperoxidized
PrxII. Ablation of PrxII exacerbated ECC force loss in mdx
muscle, while overexpression of PrxII led to a dose-dependent
protection against ECC force loss. We also demonstrate that
myoglobin participates in ECC force loss in mdx muscle, likely
through the production of hydroxyl radicals via Fenton chem-
istry. We further establish that oxidation-sensitive cysteine 272
unique to γcyto- and βcyto-actin is required to protect mdx muscle
from ECC force loss while blocking NOX2-mediated ROS pro-
duction. Finally, we show that overexpression of PrxII leads to
increased sarcolemmal damage in mdx muscle exposed to
eccentric contractions in vivo. Together, these data suggest that
ECC may drive a transient, redox-based inhibition of contractility
that protects dystrophin-deficient muscle from more catastrophic
structural damage caused by subsequent high-force contractions.
Results
Rapid recovery of ECC force loss in mdx skeletal muscle. Our
standard ECC protocol incorporates a 3 min interval between the
10 ECCs to eliminate fatigue, which is corroborated by the lack of
force loss when isolated mdx extensor digitorum longus (EDL)
muscles perform 10 more energy consumptive isometric con-
tractions32,33 (Fig. 1a). Imposing 10 ECCs on the contralateral
EDL resulted in the expected 90% drop in force; however, we
observed 65% recovery of lost force production within 2 h
(Fig. 1a). More surprisingly, the ECC force loss measured in mdx
EDL muscles was significantly attenuated when the interval
between ECC was increased from 3 to 30 min (Fig. 1b). These
data demonstrate that dystrophin-deficient mdx muscle can
rapidly recover from the perturbation imposed by one or multiple
ECCs.
Overexpression of γcyto-actin protects mdx muscle from ECC
force loss. We previously generated a mouse model that over-
expresses γcyto-actin specifically in skeletal muscle (Actg1-TG) to
levels that replace 40% of αskeletal-actin in myofibrils34 (Fig. 1c, d)
and which significantly protects mdx muscle from ECC force
loss31 (Fig. 1e). To address whether protection of mdx muscle
from ECC force loss depends specifically on the γcyto-actin iso-
form, we crossed transgenic mice (Coco) that overexpress alpha-
cardiac actin (αca-actin) specifically in skeletal muscle35 onto the
mdx background (mdx/Coco). Similar to the robust expression of
γcyto-actin in mdx/Actg1-TG (Fig. 1c, d), muscles from mdx/Coco
animals all showed high αca-actin expression that was uniformly
distributed throughout the muscle fibers (Fig. 1f, g). In contrast to
mdx/Actg1-TG mice (Fig. 1e), however, EDL muscles from mdx/
Coco animals were not significantly protected from ECC force
loss (Fig. 1h). These data led us to conclude that some feature
specific to γcyto-actin is necessary to protect mdx muscles from
ECC force loss.
Overexpression of γcyto-actin restores PrxII levels in mdx
muscle. To begin to understand how γcyto-actin overexpression
protects mdx muscle from ECC force loss, we performed 8-plex
isobaric tags for relative and absolute quantification (iTRAQ)-
based mass spectrometry analysis36 on tibialis anterior (TA)
muscle lysates isolated from mdx/Actg1-TG mice controlled
against non-transgenic mdx littermates. The iTRAQ screen
initially identified 1963 proteins representing all major protein
constituents of adult myofibers in both mdx and mdx/Actg1-TG
muscle (Supplementary Data 1). After applying a 1% false dis-
covery rate to the initial protein list, 144 high-confidence proteins
survived (Supplementary Data 2), with only 2 proteins demon-
strating significantly different levels between mdx and mdx/
Actg1-TG muscles. One differentially expressed protein was γcyto-
actin, upregulated 28-fold in mdx/Actg1-TG over mdx, while the
second protein PrxII was significantly upregulated 3.75-fold in
mdx/Actg1-TG over mdx. In addition to confirming the iTRAQ
result, western blot analysis with PrxII-specific antibodies
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demonstrated that PrxII is significantly decreased in mdx muscle
compared to WT and restored to WT levels in mdx/Actg1-TG
mice (Fig. 2a, b). In contrast, PrxII levels in mdx/Coco muscle
overexpressing αca-actin were not different from mdx muscle
(Fig. 2a, b). PrxII is one member in a family of six sulfhydryl-
dependent cellular peroxidases that reduce endogenous hydrogen
peroxide (H2O2)37. Western blot analyses for the other five family
members revealed that PrxI, PrxIII, and PrxVI levels were not
different between WT, mdx, and mdx/Actg1-TG muscles, while
PrxIV and PrxV were substantially elevated in mdx and mdx/
Actg1-TG compared to WT (Fig. 2c). Thus, PrxII was the only
peroxiredoxin significantly altered in mdxmuscle (decreased) and
restored to its WT level in mdx/Actg1-TG (Fig. 2c).
NOX2 ablation rescues PrxII levels and attenuates ECC force
loss in mdx muscle. PrxII mRNA levels were not different
between WT, mdx, and mdx/Actg1-TG muscles (Supplementary
Fig. 1a,b), suggesting the loss of PrxII protein in mdx muscle is
post-transcriptional. Recovery of PrxII levels in mdx/Actg1-TG
muscle does not seem to involve a direct interaction between
PrxII and γcyto-actin, as PrxII did not bind to F- or G-actin
in vitro (Supplementary Fig. 1c-f) or in vivo (Supplementary
Fig. 1g). Three groups recently demonstrated increased expres-
sion of NOX2 subunits in mdx muscle, which were shown to
produce significantly more ROS (ultimately in the form of H2O2)
in response to mechanical stretch27,29,30. Because pharmacologi-
cal inhibition of NOX2 by apocynin was also shown to protect
mdx muscle from ECC force loss27, we performed experiments to
elucidate the relationship between NOX2 and PrxII in mdx
muscle. We confirmed that several NOX2 subunits (gp91phox,
p67phox, p22phox, and Rac1) were increased in mdx muscle and
show that levels remained elevated in mdx/Actg1-TG muscle
(Supplementary Fig. 2a). We next compared PrxII protein levels
in WT, mdx, and mdx/p47–/– muscle, which is ablated for the
p47phox subunit necessary for NOX2 activity38. PrxII was restored
to WT levels in mdx/p47–/– muscle (Fig. 2d), supporting a role for
NOX2-dependent ROS production in the loss of PrxII from mdx
muscle.
Peroxiredoxins are known to undergo irreversible hyperoxida-
tion at conserved peroxidatic cysteine residues leading to
inactivation37,39 and degradation via the 20S proteasome40.
Therefore, we performed western blot analysis on WT, mdx,
and mdx/p47–/– muscle lysates using antibodies specific to
hyperoxidized peroxiredoxin41. The level of hyperoxidized
peroxiredoxin was significantly increased in mdx muscle
compared to WT, and was fully restored to WT levels in mdx/
p47–/– muscle (Fig. 2e). While hyperoxidized PrxII can be
reactivated by sulfiredoxin-catalyzed reduction42, we did not
detect expression of sulfiredoxin in skeletal muscle (Supplemen-
tary Fig. 2b). Finally, mdx/p47–/– muscle was significantly
protected from ECC force loss compared to mdx muscle (Fig. 2f).
Collectively, these data suggest that aberrant NOX2-dependent
ROS signaling leads to PrxII hyperoxidation and degradation in
mdx muscle.
Myoglobin knockout protects mdxmuscle from ECC force loss.
In skinned WT rodent myofibers, H2O2 can cause significant
decrements in Ca2+-activated force when myoglobin is included
in the bathing medium43. The combined effect is thought to be
caused by hydroxyl radicals produced by the Fenton reaction of
H2O2 with Fe2+ in myoglobin44. Given that mdx ECC force loss
depends on an intact muscle fiber21,24,45, we investigated whether
myoglobin mediates the inhibitory effect of ROS on the con-
tractile function of mdx muscle fibers exposed to ECC. We
crossed myoglobin knockout mice46 (mb–/–) onto the mdx
background to generate mdx/mb–/– mice. In verifying the absence
of myoglobin in mdx/mb–/– muscle by western blot analysis
(Fig. 3a), we also showed that myoglobin levels are significantly
decreased in mdx muscle and partially restored in mdx/p47–/–
muscle. Most importantly, knockout of myoglobin significantly
protected mdx muscle from ECC force loss to the same extent as
treatment of mdx muscle with the antioxidant N-acetylcysteine47
(Fig. 3b). These data suggest that myoglobin synergizes with ROS
to effect ECC force loss in mdx muscle.
PrxII ablation exacerbates ECC force loss in mdx muscle. To
further understand the role of PrxII in mdx ECC force loss, we
crossed PrxII knockout mice48 (PrxII–/–) onto the mdx back-
ground to generate mdx/PrxII–/– mice. Western blot analysis of
PrxII+/+, PrxII+/–, and PrxII–/– muscle lysates verified PrxII
antibody specificity (Supplementary Fig. 3a) and confirmed the
absence of PrxII in mdx/PrxII–/– muscle (Fig. 4a). Hematoxylin
and eosin (H&E) staining of muscle cryosections revealed that
PrxII deletion resulted in a small, but significant exacerbation of
histopathology in mdx muscle without an effect on WT muscle
histology (Fig. 4b, c). In our standard ECC protocol that imposes
a 10% change in muscle length to maximize force loss in mdx
muscle, PrxII–/– muscle was not susceptible to ECC force loss
(Supplementary Fig. 3b), while ECC force loss in mdx/PrxII–/–
tracked to that measured in mdx (Fig. 4d). However,mdx/PrxII–/–
muscles showed significantly greater force loss than mdx muscle
when exposed to a milder ECC protocol utilizing a 5% length
change that elicits lower eccentric force (Fig. 4d). These data show
that PrxII knockout increases the susceptibility of mdx muscle to
ECC force loss.
PrxII overexpression protects mdxmuscle from ECC force loss.
Based on the detrimental effect of PrxII ablation on mdx muscle
(Fig. 4), we tested the hypothesis that PrxII overexpression would
protect mdx muscle from ECC force loss. We generated four lines
of transgenic mice that overexpress PrxII specifically in skeletal
muscle and crossed each line onto the mdx background to obtain
four distinct lines of mdx/PrxII-TG mice. Quantitative western
blot analysis demonstrated PrxII overexpression to 1×, 12×, 58×
and 112× over WT levels in the four lines (Supplementary Fig. 4a,
b). In our standard ECC protocol, we observed a clear dose-
dependent protection of mdx muscle from ECC force loss with
the greatest effect measured when PrxII was overexpressed 58×
over WT (Fig. 5a, b). H&E staining of muscle cryosections from
the 58× overexpressing mdx/PrxII-TG line revealed a small but
significant decrease in the number of centrally nucleated fibers
compared to mdx (Fig. 5c, d). Because restoration of PrxII to 1×
WT levels did not protect mdx muscle from ECC force loss
(Fig. 5a, b), the loss of PrxII from mdx muscle is not the primary
cause of ECC force loss in mdx muscle, but rather likely a con-
sequence of excessive ROS produced by NOX2 in response to
mechanical activation.
Protection of mdx muscle from ECC force loss by γcyto-actin
requires Cys272. The protection of mdx muscle from ECC force
loss by overexpression of γcyto-actin, but not αca-actin (Fig. 1c–h)
led us to re-examine their highly homologous primary sequences.
Interestingly, γcyto-actin and βcyto-actin each contain 6 Cys resi-
dues while αsk-actin and αca-actin only contain 5 Cys residues
(Supplementary Fig. 5). The additional Cys unique to γcyto-actin
and βcyto-actin is located at position 272 (Supplementary Fig. 5,
green highlight, blue circle) and has been shown to be the most
reactive with H2O249. To investigate the role of Cys272 within
γcyto-actin in protecting mdx muscle from ECC force loss, we
generated transgenic mouse lines overexpressing the C272A
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mutant of γcyto-actin (C272A-TG) as well as βcyto-actin (Actb-
TG) specifically in skeletal muscle and crossed the lines onto the
mdx background to identify those that best match γcyto-actin
overexpression in mdx/Actg1-TG (Fig. 6a). In addition, recom-
binant γcyto-actin (for mdx/C272A-TG) and platelet actin (for
mdx/Actb-TG) were used to generate standard curves for quan-
titative western blot analysis to verify equivalent expression of
each actin transgene (Supplementary Fig. 6a-c). Uniformity of
C272A and βcyto-actin overexpression was verified by immuno-
fluorescence analysis (Fig. 6b), while H&E staining revealed no
obvious change in the histopathology of mdx muscle associated
with overexpression of C272A or βcyto-actin (Supplementary
Fig. 6d). Most interestingly, βcyto-actin overexpression protected
mdx muscle from ECC force loss to the same extent as γcyto-actin,
while ECC force loss in mdx/C272A-TG was not different from
mdx (Fig. 6c). Finally, we measured the rate of NOX2-dependent
ROS production in response to cyclic stretch of single myofibers38
isolated from WT, mdx, mdx/Actg1-TG, mdx/C272A-TG, and
mdx/Actb-TG mice (Fig. 6d). Stretch-dependent, NOX2-
mediated ROS signaling was significantly greater in mdx and
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Fig. 1 Eccentric contraction-induced force loss in mdx muscle recovers rapidly and is partially protected by overexpression of γcyto-actin, but not αcardiac-
actin. a Recovery of isometric force production in isolated extensor digitorum longus (EDL) muscles from mdx mice subjected to 10 maximal isometric or
eccentric contractions. Values are expressed as a percentage of the isometric force measured before the 10 contractions (Pre) for each timepoint listed; n
= 4 for both conditions. *P < 0.05, ***P < 0.001 compared with Post 0’; two-way ANOVA. b Increasing the time interval between eccentric contractions
from 3 to 30min significantly diminishes the measured force loss in EDL muscles from mdx mice; n= 4 for both conditions. *P < 0.05, **P < 0.01, ***P <
0.001 compared to 3min Rest; two-way ANOVA. c Immunoblot analysis of γcyto-actin in tibialis anterior (TA), extensor digitorum longus (EDL),
gastrocnemius (Gastroc), and soleus muscles from mdx/Actg1-TG mice versus non-transgenic mdx littermates. d Immunofluorescence analysis of γcyto-
actin (green), laminin (red), and DAPI (blue) in 10 µm cryosections of quadriceps muscle from mdx/Actg1-TG mice versus non-transgenic mdx littermates.
e EDL muscles isolated from mdx/Actg1-TG mice and non-transgenic mdx littermates were subjected to 10 eccentric contractions and the force measured
at each contraction expressed as a percentage of the force produced during the first contraction; n= 4 for both genotypes. *P < 0.05, **P < 0.01, ***P <
0.001 compared to mdx; two-way ANOVA. f Immunoblot analysis of αca-actin in tibialis anterior (TA), extensor digitorum longus (EDL), gastrocnemius
(Gastroc), and soleus muscles from mdx/Coco mice versus non-transgenic mdx littermates. g Immunofluorescence analysis of αca-actin (green), laminin
(red), and DAPI (blue) in 10 µm cryosections of quadriceps muscle from mdx/Coco mice versus non-transgenic mdx littermates. h EDL muscles isolated
from mdx/Coco mice and non-transgenic mdx littermates were subjected to 10 eccentric contractions and the force measured at each contraction
expressed as a percentage of the force produced during the first contraction; n= 4 for both genotypes. Throughout, error bars represent means ± SEM
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mdx/C272A-TG compared to WT, mdx/Actg1-TG, or mdx/Actb-
TG (Fig. 6d). These data demonstrate that γcyto-actin and βcyto-
actin overexpression protects mdx muscle from ECC force loss by
blocking the stretch-dependent NOX2-mediated production of
ROS and show that Cys272 is necessary for inhibition.
Increased sarcolemmal damage in mdx muscle overexpressing
PrxII following in vivo ECC. The rapid but mostly reversible
inhibition of force production in mdx muscle exposed to ECC led
us to consider that it may actually protect mdx muscle from
damage analogous to an electrical circuit breaker. However, dis-
abling the circuit breaker could lead to greater damage to mdx
muscle exposed to ECC. To test this hypothesis, we measured
sarcolemmal damage in WT, mdx, and 58X mdx/PrxII-TG
following 70 eccentric contractions in vivo (Fig. 7a, b). While the
unstressed contralateral muscle of mdx/PrxII-TG mice displayed
similar levels of Evans blue dye (EBD) uptake compared to mdx,
they presented with significantly more (27% vs. 14% in mdx)
EBD-positive myofibers following 70 in vivo eccentric contrac-
tions (Fig. 7a, b). These data suggest that disabling ROS-mediated
inhibition of force loss leads to greater injury following in vivo
ECC in mdx muscle.
Discussion
Our data best fit a model in which PrxII functions as an off-
switch to regulate stretch-activated NOX2 signaling in normal
skeletal muscle50, but is lost from mdx muscle through hyper-
oxidation and proteolytic degradation effected by aberrant
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Fig. 2 Peroxiredoxin-2 is significantly decreased in mdx skeletal muscle and restored by γcyto-actin overexpression and genetic ablation of NOX2 activity. a
Immunoblot analysis of PrxII, dystrophin, utrophin, and GAPDH in WT, mdx, mdx/Actg1-TG, and mdx/Coco gastrocnemius muscles. b Immunoblot
quantitation demonstrated that PrxII levels in mdx skeletal muscle were 16.5 ± 0.03% of WT and restored in mdx/Actg1-TG muscle to levels not different
fromWT, but not in mdx/Coco muscle; n= 5 for WT and mdx; n= 7 for mdxActg1-TG and mdx/Coco. ***P < 0.001, ns no significance; one-way ANOVA. c
Immunoblot analysis of peroxiredoxins 1–6 in gastrocnemius muscles from WT, mdx, and mdx/Actg1-TG mice. PrxII was the only peroxiredoxin isoform
that was both altered in mdx compared to WT, and also restored to its WT level by muscle-specific γcyto-actin overexpression. d Immunoblot analysis of
PrxII in WT, mdx, and mdx/p47–/– gastrocnemius muscles demonstrated a restoration of PrxII to WT levels in mdx/p47–/– muscle; n= 4 for each genotype.
***P < 0.001, ns no significance; one-way ANOVA. e Immunoblot analysis demonstrated significantly elevated hyperoxidized peroxiredoxin (PrxSO3) in
mdx compared to WT, and restored to WT levels in mdx/p47–/– gastrocnemius muscles; n= 4 for each genotype. ***P < 0.001, ns no significance; one-way
ANOVA. f EDL muscles isolated from WT, mdx, p47–/–, and mdx/p47–/– mice were subjected to 10 eccentric contractions and the forces measured
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0.05, ***P < 0.001 compared to mdx; two-way ANOVA. Throughout, error bars represent means ± SEM
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NOX2-mediated ROS production. PrxII is known to suppress
redox-mediated growth factor signaling51–53, while NOX2 in mdx
skeletal muscle has been demonstrated to produce significantly
more ROS38, particularly in response to mechanical stretch as
occurs during ECC27,29,30,54. Importantly, treatment with the
NOX2 inhibitor apocynin27, the non-specific antioxidant N-
acetylcysteine47, or catalase overexpression55 has been shown to
protect mdx muscle from ECC force loss, mirroring the effect we
observed in mdx/Actg1-TG (Fig. 1e), mdx/p47–/– (Fig. 2f), mdx/
mb–/– (Fig. 3b), mdx/PrxII-TG (Fig. 5a), and mdx/Actb-TG EDL
muscles (Fig. 6c) (for more physiological parameters of all mouse
lines, see Supplementary Table 1).
Our stretch-activated ROS experiments with single myofibers
from transgenic models overexpressing γcyto-actin, βcyto-actin, or
the C272A mutant of γcyto-actin (Fig. 6d) suggest that cyto-
plasmic actin overexpression directly inhibits NOX2 activity in
mdx skeletal muscle. In vitro binding experiments and studies in
nonmuscle cells have shown that actin can inhibit NOX2 activity
by directly binding and sequestering the p40phox, p47phox, and/or
p67phox regulatory subunits56,57. Alternatively, the additional
redox-sensitive Cys272 unique to γcyto- and βcyto-actins49,58 may
serve to shunt ROS-mediated oxidation away from conserved
sulfhydryls necessary for contractile function. Future experiments
will address both possibilities.
One poorly understood feature of ECC force loss in mdx
muscle is its dependence on intact myofibers, because skinned
fibers from mdx mice are no more susceptible to ECC than
WT21,24,45. In studies of muscle fatigue, ROS in the form of H2O2
is thought to exert inhibitory effects on contractile proteins, yet
extremely high concentrations of H2O2 are required to cause
significant decrements in Ca2+-activated force loss in skinned
myofibers44,59. However, the concentration of H2O2 required to
elicit force loss is greatly reduced when myoglobin is included in
the bathing medium43,44, which results in the production of
highly reactive hydroxyl radicals through the reaction of H2O2
with Fe2+ in myoglobin44. Our experiments in mdx/mb–/– mice
(Fig. 3) suggest that myoglobin and H2O2 may catalyze similar
Fenton chemistry in mdx muscle to cause ECC force loss with
concomitant oxidative degradation of myoglobin.
While the ROS-based perturbations tested here by us and
reported by others previously27,47,55,60 all demonstrated sig-
nificant protection of mdx muscle from ECC force loss, the
measured protection is incomplete. Other studies have implicated
elevated cytosolic calcium61–64, loss of neuromuscular junction or
sarcolemmal membrane excitability19,20, neuronal nitric oxide
synthase25, and Akt/PKB signaling24 in mdx ECC force loss and
our results are neither incompatible with nor mutually exclusive
of such mechanisms. For example, NOX2 negatively regulates Akt
activation in skeletal muscle exposed to oxidative stress65, while
the activity of ion channels important for membrane excitability
are sensitive to oxidation66. Although stretch-activated calcium
channels are clearly one downstream effector of the ROS pro-
duced by NOX228, it is not clear how an increase in cytosolic
calcium could affect rapidly reversible ECC force loss as reported
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Fig. 3 Genetic ablation of myoglobin partially protects mdx muscle from eccentric contraction-induced force loss. a Immunoblot analysis demonstrated the
absence of myoglobin in mdx/mb–/– muscle, that myoglobin levels are decreased in mdx, and that myoglobin levels are partially restored in mdx/p47–/–
gastrocnemius muscle; n= 4 for each genotype. *P < 0.05, **P < 0.01, ***P < 0.001; one-way ANOVA. b EDL muscles isolated from mdx and mdx/mb–/–
mice, or mdx muscles treated with 20 mM N-acetylcysteine (NAC) were subjected to 10 eccentric contractions and the forces measured expressed as a
percentage of the force generated during the first eccentric contraction; n= 4 for WT and mdx+NAC; n= 9 for mdx/mb–/–; *mdx+NAC significantly
different from mdx (P≤ 0.05); #mdx/mb–/– significantly different from mdx (P≤ 0.05); two-way ANOVA. Throughout, error bars represent means ± SEM
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here (Fig. 1a, b) and elsewhere67,68. Perhaps the rapidly reversible
component of ECC force loss, measured here over the course of 2
h, is due to reversible oxidation of one or more proteins reg-
ulating muscle contraction, while the slowly reversible compo-
nent, or force loss that is recovered in the timeframe of several
days69, is due to calcium-activated proteolysis of other muscle
regulatory proteins. Alternatively, both the rapidly reversible and
slowly reversible components of ECC force loss in mdx muscle
could result from oxidative stress. In some pathological states,
peroxiredoxins (including PrxII) are subject to over-oxidation
such that reversibly sulfenylated cysteine residues become irre-
versibly sulfinylated or sulfonylated53,70. Such hyperoxidation
may occur in proteins involved with contractility in mdx muscle,
leading to their irreversible inactivation and contributing to the
slowly reversible component of ECC force loss.
As noted in the Introduction, ECC force loss in mdx muscle is
often referred to as “contraction-induced injury,” or “contraction-
induced damage,” and muscle damage is operationally defined “as
weakness which recovers very slowly after activity with a time
course (4–8 days) similar to repair or regeneration”18. We mea-
sured rapid recovery of force in isolated mdx EDL muscles
exposed to ECC (Fig. 1a). While our rapid recovery data are
supported by other studies67,68, they are incompatible with the
above definition of muscle damage. On the other hand, the
rapidly reversible component of ECC force loss fits well with a
reversible ROS-mediated inhibition of contractile force. This
immediate and reversible inhibition of force in mdx may benefit
the muscle in the long run, since more injurious contractions
performed in vivo on mdx mice with decreased ROS signaling
(mdx/PrxII-TG) led to increased sarcolemmal permeability
(Fig. 7). Rather than serving as a readout for muscle damage, ours
and others’ data collectively lead us to propose that ECC force
loss may instead function as an adaptive circuit breaker that
protects dystrophin-deficient muscle from potentially cell-lethal
structural damage caused by continually repeated high force
contractions.
Methods
Mice. All animals were housed and treated in accordance with the standards set by
the University of Minnesota Institutional Animal Care and Use Committee. All
animal experiments were approved by the University of Minnesota Institutional
Animal Care and Use Committee under protocol numbers 1207A17501, 1506-
32699A, and 1806-36018A. Mice were maintained on regular diet in a specific-
pathogen-free facility on a 12 h light/dark cycle with continuous access to food and
water. All wild-type mice used in this study were on the C57BL/10SnJ background.
All transgenic overexpression mice are skeletal muscle-specific using the human
skeletal actin (HSA) promoter. All mice on the mdx background utilized the
C57BL/10ScSn-Dmdmdx/J strain of mdx mice from The Jackson Laboratory.
Transgenic mice overexpressing γcyto-actin on the mdx background (mdx/Actg1-
TG) have been previously described31. Transgenic mice overexpressing αcardiac-
actin (Coco) have been previously described35 and bred onto the mdx background
in this study. Mice with a genetic deletion of the NOX2 scaffolding subunit p47phox
(p47–/–) were obtained from The Jackson Laboratory (B6(Cg)-Ncf1m1J/J) and bred
onto the mdx background as previously described38. Mice with a genetic knockout
of myoglobin (mb–/–) have been previously described46 and were bred onto the
mdx background in this study. Mice lacking peroxiredoxin-2 (PrxII–/–) have been
previously described48 and were rederived from sperm donated by Dr. Dae-Yeul
Fig. 4 Genetic ablation of peroxiredoxin-2 further sensitizes mdx muscle to
eccentric contraction-induced force loss. a Immunoblot analysis of PrxII in
WT, mdx, PrxII–/–, and mdx/PrxII–/– gastrocnemius demonstrated the
absence of PrxII in PrxII–/– and mdx/PrxII–/– muscle. b A small but
significant increase in the percentage of centrally nucleated fibers (%CNFs)
was seen in mdx/PrxII–/– versus mdx muscle quantified from 10 µm
cryosections of TA stained with H&E. n= 3 for each genotype. **P < 0.01
for mdx/PrxII–/– compared to mdx; one-way ANOVA. c Representative
images of 10 µm cryosections of TA from WT, mdx, PrxII–/–, and mdx/
PrxII–/– stained with H&E. Scale bar: 50 µm. d EDL muscles isolated from
mdx and mdx/PrxII–/– mice were subjected to 10 eccentric contractions
with either a 5% or 10% length change, and the forces measured expressed
as a percentage of the force generated during the first eccentric
contraction. There was no significant difference between mdx and mdx/
PrxII–/– with a 10% length change, but a 5% length change revealed a
significant difference between mdx and mdx/PrxII–/– for contractions 6–10;
n= 4 for each genotype/condition. *P < 0.05, **P < 0.01, ***P < 0.001
compared to mdx; two-way ANOVA. Throughout, error bars represent
means ± SEM
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Yu (Korean Research Institute of Bioscience and Biotechnology) and bred onto the
mdx background in this study. Transgenic mice overexpressing peroxiredoxin-2
(PrxII-TG), γcytoC272A (C272A-TG), and βcyto-actin (Actb-TG) are described in this
paper (Methods – Cloning and generation of transgenic mice), and all three were
bred onto the mdx background, resulting in mdx/PrxII-TG, mdx/C272A-TG, and
mdx/Actb-TG mice. For all transgenic lines on the mdx background, non-
transgenic mdx littermates were used as controls. Animals used for physiological
experiments were all 3 months of age, while mice used for all other experiments
were 3–6 months of age. All mice used in this study were male.
Antibodies and reagents. Primary antibodies used for western blotting were:
mouse monoclonal anti-γcyto-actin71 (1:1000; clone 2–4), mouse monoclonal anti-
αcardiac-actin (1:1000; Sigma, A9357), rabbit polyclonal anti-PrxII (1:1,000; Sigma,
R8656), mouse monoclonal anti-Dystrophin (1:100; Leica, NCL-DYS1), mouse
monoclonal anti-Utrophin (1:100; Santa Cruz, sc-33700), mouse monoclonal anti-
GAPDH (1:10,000; Sigma, G8795), rabbit polyclonal anti-GAPDH (1:10,000;
Sigma, G9545), rabbit polyclonal anti-PrxI (1:500; Abcam, ab15571), mouse
monoclonal anti-PrxIII (1:500; Abcam, ab16751), mouse monoclonal anti-PrxIV
(1:500; Abcam, ab16943), mouse monoclonal anti-PrxV (1:500; Abcam, ab16944),
rabbit polyclonal anti-PrxVI (1:1000; Sigma, P0058), rabbit polyclonal anti-PrxSO3
(1:200; Abcam, ab16830), rabbit polyclonal anti-Myoglobin (1:5000; Dako, A0324),
mouse monoclonal anti-βcyto-actin (1:1000; Sigma, A1978), mouse monoclonal
anti-gp91phox (1:1000; BD Biosciences, 611414), mouse monoclonal anti-p67phox
(1:1000; BD Biosciences, 610912), rabbit polyclonal anti-p22phox (1:200; Santa
Cruz, sc-20781), mouse monoclonal anti-Rac1 (1:2000; Cytoskeleton, ARC03),
rabbit polyclonal anti-p47phox (1:1000; EMD Millipore, 07-500), rabbit polyclonal
anti-p40phox (1:500; EMD Millipore, 07-501), and rabbit polyclonal anti-
Sulfiredoxin (1:1000; Proteintech, 14273-1-AP). Secondary antibodies used for
western blotting were: DyLight 680 Goat anti-Mouse IgG (CST, 5470S), DyLight
680 Goat anti-Rabbit IgG (CST, 5366S), DyLight 800 Goat anti-Mouse IgG (CST,
5257S), and DyLight 800 Goat anti-Rabbit IgG (CST, 5151S) all at 1:10,000
dilutions.
Primary antibodies used for immunofluorescence were: rabbit polyclonal anti-
γcyto-actin71 (1:500; clone 7577), mouse monoclonal anti-αcardiac-actin (1:250;
Sigma, A9357), rabbit polyclonal anti-Laminin (1:1000; Sigma, L9393), rat
monoclonal anti-Laminin (1:1000; Sigma, L0663), mouse monoclonal anti-βcyto-
actin-FITC (1:500; Abcam, ab6277), and rabbit polyclonal anti-Dystrophin72 (1:20;
clone Rb2). Secondary antibodies used for immunofluorescence were: Alexa Fluor
488 Donkey anti-Mouse IgG (ThermoFisher, A-21202), Alexa Fluor 488 Donkey
anti-Rabbit IgG (ThermoFisher, A-21206), Alexa Fluor 488 Goat anti-Rat IgG
(ThermoFisher, A-11006), Alexa Fluor 568 Donkey anti-Mouse IgG
(ThermoFisher, A-10037), Alexa Fluor 568 Goat anti-Rabbit IgG (ThermoFisher,
A-11011), and Alexa Fluor 568 Goat anti-Rat IgG (ThermoFisher, A-11077) all at
1:500 dilutions.
Other reagents used were DH5α competent cells (Invitrogen, 18258012),
DH10Bac competent cells (Invitrogen, 10361012), Sf9 insect cells (ATCC, CRL-
1711), N-acetylcysteine (Sigma, A7250), DCFH-DA (6-Carboxy-2′,7′-
Dichlorodihydrofluorescien Diacetate) (Invitrogen, C-400), gp91ds-tat (NOX2-
specific peptide inhibitor) (Bio-Synthesis Inc., Lewisville, TX), FLAG peptide
(University of Minnesota Genomics Center, Minneapolis, MN), anti-FLAG M2
affinity gel (Sigma, A2220), and human platelet actin protein (Cytoskeleton,
APHL99).
Ex vivo EDL force measurements. Contractile functions of EDL muscles were
assessed according to methods described previously73. Mice were anesthetized with
sodium pentobarbital (75–100 mg/kg body mass). EDL muscles were dissected and
mounted on a 300B-LR dual-mode muscle lever system (Aurora Scientific Inc.)
with 5–0 suture in a 1.2 mL bath assembly with oxygenated (95:5% O2/CO2) Krebs-
Ringer bicarbonate (Krebs) buffer maintained at 25 °C. The stimulator and muscle
lever system was controlled by computer using a KPCI-3108 interface board
(Keithley Instruments) and TestPoint software (SuperLogics). Muscles were
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adjusted to their anatomical optimal length (Lo) based on resting tension, with
length being measured from the distal myotendonous junction to the proximal
myotendonous junction using digital calipers. Prior to performing eccentric con-
tractions, maximal isometric tetanic force (Po) was measured every 2 min by sti-
mulating the muscle to contract for 200 ms at 175 Hz until force plateaued, with
this value being designated “pre Po”, or simply “Pre”. In our standard ECC pro-
tocol, a series of 10 eccentric contractions were performed and the peak force of
each contraction was recorded. For each ECC force measurement, the muscle was
passively shortened to 95% Lo and then stimulated for 200 ms while the muscle was
simultaneously lengthened to 105% Lo at a velocity of 0.5 Lo/s. Each eccentric
contraction was separated by 3 min of rest before performing the next eccentric
contraction to prevent fatigue74. The force measured at each eccentric contraction
was expressed as a percentage of the force produced during the first (“initial”)
contraction. The value of “n” for all ECC experiments is defined as “number of
mice”, and only one EDL per mouse was used for each experiment. This standard
ECC protocol was used in Fig. 1e, h, Fig. 2f, Fig. 3b, Fig. 4d (10%: mdx and 10%:
mdx/PrxII–/–), Fig. 5a, Fig. 6c, and Supplementary Fig. 3b. Experiments where
variations of the standard ECC protocol were used are explained below.
For Fig. 1a, mdx muscles were subjected to either the standard ECC protocol
described above or the same protocol substituting isometric contractions for
eccentric contractions performed on the contralateral EDL. After each 10-
contraction protocol, Po was measured immediately (Post 0’) as well as at the 20,
40, 60, 90, and 120 min timepoints (Post 20’, Post 40’, etc.). Each Po was then
expressed as a percentage of the Po measured before the 10 eccentric or isometric
contractions (Pre). For the eccentric protocol, statistical significance was
determined for the Po measured at Post 20’ through Post 120’ compared to the Po
measured at Post 0’ (see Statistical analysis).
In Fig. 1b, mdx EDLs were subjected to only 5 eccentric contractions. The first
muscle used a standard 3 min of rest between each eccentric contraction, while the
contralateral muscle was allowed 30 min of rest between contractions.
Figure 3b involves a group where N-acetylcysteine (NAC) treatment was
performed on mdx EDLs. For this group, NAC (Sigma-Aldrich) was dissolved
directly into Krebs Buffer at 20 mM immediately prior to bath assembly47. The
control mdx group used standard Krebs Buffer without NAC. For both groups,
EDL muscles were incubated for 30 min so NAC could efficiently penetrate the
muscle before being subjected to the standard ECC protocol.
For Fig. 4d, the standard ECC protocol was used for 10%: mdx and 10%: mdx/
PrxII–/– experiments (solid lines). For the other two experiments (dash lines), the
standard ECC protocol was used except that a 5% length change was performed
instead of a 10% change. Here, EDL muscles were passively shortened to 97.5% Lo
and then stimulated for 200 ms while the muscle was simultaneously lengthened to
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mdx/C272A-TG. ***P < 0.001, ns no significance compared to WT; one-way ANOVA. Throughout, error bars represent means ± SEM
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102.5% Lo at 0.25 Lo/s, resulting in lower peak eccentric force being generated
compared to the 10% length change.
Immunoblot analysis. Gastrocnemius muscles from mice of the indicated geno-
types were dissected, flash frozen in liquid N2, pulverized to a powder with a liquid
N2-cooled mortar and pestle, and resuspended in 1% sodium dodecyl sulfate (SDS)
in phosphate-buffered saline (PBS) with protease inhibitors (100 nM aprotinin, 1
mM benzamidine, 10 µM E-64, 10 µM leupeptin, 1 mM pepstatin A, 1 mM phe-
nylmethanesulfonylfluoride, 1 µM calpain inhibitor I, and 1 µM calpeptin). Sam-
ples were then incubated at room temperature (RT) with end-over-end rotation for
30 min, followed by centrifugation at 20,817 × g for 10 min to clear lysates of
insoluble material. Total protein concentration of the lysates was determined by
A280 measurement (NanoDrop 1000, ThermoFisher Scientific). Lysates were then
diluted to equal concentrations before Laemmli sample buffer was added and
boiled for 5 min. Equal amounts of protein were then separated by
SDS–polyacrylamide gel electrophoresis (SDS-PAGE), transferred to poly-
vinylidene difluoride (PVDF) membranes, blocked with 5% milk in PBS, and
incubated with the indicated primary antibodies overnight at 4 °C. The next day,
membranes were washed 4 × 5min in 0.1% Tween in PBS before incubation with
DyLight secondary antibodies (1:10,000 each) for 1 h at RT. Membranes were again
washed 4 x 5 min before being imaged with an Odyssey Infrared Scanner (LI-COR
Biosciences). Protein bands were then quantified using LI-COR Image Studio
software.
Muscle histology and immunofluorescence. TA muscles from each mouse line
were cryopreserved in melting isopentane for 30 s and 10 µm transverse cryosec-
tions were obtained (Leica CM3050 S). For histology, sections were stained with
H&E and imaged on a Leica DM5500 B microscope equipped with a Leica HC
PLAN APO 20× objective. Centrally nucleated fibers (CNFs) were counted using
the Cell Counter plugin on ImageJ software (NIH) and expressed as a percentage of
the total number of myofibers (%CNFs). For immunofluorescence, sections were
fixed in 4% paraformaldehyde in PBS at RT for 10 min and subsequently washed
three times in PBS before being permeabilized in 0.1% Triton X-100 in PBS for 10
min at RT. Sections were then blocked in 5% bovine serum albumin (BSA) and
0.1% Triton X-100 in PBS for 1 h at RT before incubating with primary antibodies
overnight at 4 °C. Slides were then washed three times in PBS before incubating
with Alexa Fluor secondary antibodies (1:500 each) for 1 h at RT. Sections were
finally wash three times in PBS and mounted in ProLong Gold Antifade with 4′,6-
diamidino-2-phenylindole (DAPI) to visualize nuclei (ThermoFisher Scientific).
Images were acquired on a Deltavision PersonalDV deconvolution microscope
equipped with an Olympus UApo 20x objective.
iTRAQ proteomics. TA muscles were dissected from 5 mdx/Actg1-TG mice and 3
non-transgenic mdx littermates and pulverized into powder with a liquid nitrogen-
cooled mortar and pestle. We closely followed the protein extraction and pre-
paration steps as well as offline peptide fractionation described previously75 with
slight modifications. We added 10 µL of lysis buffer per milligram of tissue for
protein extraction and sonicated. A 105 µL aliquot of each lysate was run in the
Barocycler NEP2320 (Pressure Biosciences, South Easton, MA) after which a
Bradford assay was performed to determine protein concentrations. We digested
100 µg of each sample with trypsin, performed solid-phase extraction (SPE) clean-
up, and reacted 40 µg of each of the eight protein samples with one of the iTRAQ®
8-plex reagents (Sciex, Framingham, MA). iTRAQ labels 113, 114, and 115 were
used to label peptides from the 3 mdx samples, while iTRAQ labels 116, 117, 118,
119, and 121 were used to label peptides from the 5 mdx/Actg1-TG samples. We
mixed equal aliquots of each protein sample (40 µg), processed by SPE clean-up,
and performed peptide fractionation by liquid chromatography (LC). We per-
formed the second dimension capillary LC separation of peptides in-line with an
Orbitrap Velos mass spectrometer (MS) as previously described76. Slight variations
in the mass spectrometer acquisition method were: lock mass was not used, HCD
activation time was 20 msec, dynamic exclusion duration was 15 s, and the mini-
mum signal threshold for data dependent trigger was 20,000 counts.
We converted the raw MS datafiles to MGF files with MS Convert from
ProteoWizard Toolkit77. We used ProteinPilot™ v4.5 (Sciex, Framingham, MA) for
the database search and quantification report with the following parameters:
National Center for Biotechnology Information (NCBI) RefSeq mouse (Taxonomy
ID: 10088) protein database combined with the contaminants database (http://
www.thegpm.org/cRAP/index.html); 8-plex peptide label sample type; cysteine
methyl methanethiosulfonate; trypsin; instrument Orbi MS (1–3ppm) Orbi MS/
MS; biological modifications ID focus; thorough search effort; detected protein
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3 for WT and mdx; n= 4 for mdx/PrxII-TG. *P < 0.05 compared to WT-ECC, #P < 0.05 compared to mdx-ECC; one-way ANOVA
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threshold 0.05 (10%); competitive error margin 2.00; and false discovery rate (FDR)
analysis invoked (with reversed database). FDR calculations were performed in
ProteinPilot™ with the concatenated forward and reversed protein sequence
databases according to the method previously reported78. ProteinPilot™ calculates
an average protein relative fold change between two conditions along with a 95%
confidence interval for the fold change and a P value for a test of the null
hypothesis unity (1:1 ratio), which helps assess the statistical significance of a fold
change.
It should be noted that we originally attempted to perform iTRAQ proteomics
on 4 mdx/Actg1-TG mice versus 4 non-transgenic mdx littermates. After obtaining
the high-confidence protein list results, we discovered that the sample labeled with
iTRAQ 116, initially thought to be an mdx mouse, displayed significantly higher
levels of γcyto-actin, consistent with iTRAQ labels 117, 118, 119, and 121 (mdx/
Actg1-TG mice). We then re-genotyped the set of mice used in the iTRAQ
proteomic screen, which revealed that the mouse labeled with iTRAQ 116 was
indeed mdx/Actg1-TG, and that this mouse had been mis-genotyped or mis-
labeled, resulting in 5 mdx/Acg1-TG mice and 3 non-transgenic mdx littermates
instead of 4 of each genotype. Uncovering this mistake increased our confidence in
the iTRAQ experiment, as the data from the screen itself unveiled the error.
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
Gastrocnemius of WT, mdx, and mdx/Actg1-TG mice were flash frozen in liquid
N2 and pulverized to a powder with a cooled mortar and pestle. Total RNA was
then extracted from each sample using the Aurum Total RNA Mini Kit (Bio-Rad)
following the manual’s instructions. RNA concentration and purity (A260/280 ratio)
were determined using a NanoDrop 1000 spectrophotometer (ThermoFisher Sci-
entific). Reverse transcription was performed using the iScript Advanced com-
plementary DNA (cDNA) Synthesis Kit for qRT-PCR (Bio-Rad) using the same
initial RNA amount (1 µg) for all samples. qPCR reactions were prepared with the
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) and quantified on a
CFX96 Real Time System C1000 Touch Thermal Cycler (Bio-Rad). Primer sets for
both PrxII and HPRT (loading control) were generated with Primer-BLAST soft-
ware (NIH) to amplify across an exon junction and are listed in Supplementary
Table 2. Significance of gene expression differences was determined by one-way
analysis of variance (ANOVA) with Tukey's post hoc test analysis. Resulting qRT-
PCR reactions were further run on a 1% agarose gel for visualization.
Protein expression and purification. FLAG-tagged PrxII and Fascin-1 proteins
were expressed and purified in Sf9 insect cells using the Bac-to-Bac protocol
(Invitrogen). Briefly, recombinant baculoviral DNA was transfected into a small
culture of Sf9 insect cells using CellFectin II (Invitrogen). After 4 days, the media
containing the recombinant baculovirus were harvested and the transfected cells
were analyzed for protein expression by anti-FLAG western blot. Once expression
was validated, large (250 mL) cultures were incubated for 3 days with amplified
baculovirus before being harvested for protein purification. For purification, cells
were lysed using 1% Triton X-100 in PBS (8 mM NaH2PO4, 42 mM Na2HPO4, 150
mM NaCl, pH 7.5) containing protease inhibitors (100 nM aprotinin, 1 mM ben-
zamidine, 10 µM E-64, 10 µM leupeptin, 1 mM pepstatin A, and 1 mM phe-
nylmethanesulfonylfluoride) and protein was purified using ANTI-FLAG M2
affinity gel (Sigma-Aldrich) as previously described79–81. Proteins were dialyzed
into PBS overnight at 4 °C before being concentrated and used in in vitro F-actin
and G-actin binding assays (Supplementary Fig. 1c-f). Recombinant γcyto-actin was
expressed in the Bac-to-Bac insect cell expression system and purified as previously
described82,83 before being used as a standard curve in determination of C272A-
TG and Actb-TG transgene concentrations (Supplementary Fig. 6a,b).
F-actin cosedimentation assay. A previously described F-actin high speed cose-
dimentation assay82 was used to measure binding properties of PrxII and Fascin-1
(positive control). Briefly, human platelet actin (Cytoskeleton) was resuspended in
G-Buffer (5 mM Tris-HCl pH 8.0, 0.2 mM CaCl2, 0.2 mM ATP, and 0.5 mM DTT),
then induced to polymerize with the addition of 10× Polymerization Buffer (100
mM Tris pH 7.5, 500 mM KCl, 20 mM MgCl2, and 10 mM ATP). Recombinant
FLAG-PrxII or FLAG-Fascin-1 (1 µM each) was then incubated with various
concentrations of F-actin (0–15 µM) for 30 min at RT. Samples then underwent
high speed centrifugation at 100,000 × g for 30 min at 4 °C. Resulting supernatant
and pellet fractions were subjected to SDS-PAGE, stained with Coomassie blue,
and scanned using the Licor Odyssey system allowing quantification of supernatant
and pellet fractions. The values from these experiments were plotted in GraphPad
Prism software and nonlinear regression analysis was performed.
G-actin binding assay. Human platelet actin (Cytoskeleton) was resuspended in
G-Buffer (5 mM Tris-HCl pH 8.0, 0.2 mM CaCl2, 0.2 mM ATP, and 0.5 mM DTT)
to maintain actin in its globular form (G-actin). Then, 400 µL mixtures of 1 µM G-
actin alone (negative control) and 1 µM G-actin+ 1 µM FLAG-PrxII (experiment)
were made. Then, 100 µL of both mixtures were taken as the “Load” fraction. Then,
100 µL of each protein mixture was added to 25 µL of ANTI-FLAG M2 affinity
beads and incubated for 1 h at 4 °C with end-over-end rotation. The beads were
then centrifuged at 106 × g for 3 min at 4 °C and the supernatant was collected as
the “Void” fraction. The beads were then washed three times with 400 µL G-buffer
before adding 100 µL of 0.1 mg/mL FLAG peptide in G-Buffer and incubating at
RT for 10 min. Samples were then centrifuged as before and the supernatants were
collected as the “Elute” fraction. To ensure the G-actin was indeed in its globular
form, 100 µM of both protein mixtures was incubated at RT for 30 min before
being subjected to high-speed centrifugation (100,000 x g) for 30 min at 4 °C. The
supernatant and pellet fractions were then collected and run with each Load, Void,
and Elute fraction on SDS-PAGE. Gels were then Coomassie stained and scanned
on the Licor Odyssey imaging system.
PrxII immunoprecipitation. PrxII was immunoprecipitated from mdx/Actg1-TG
muscle using the Pierce Crosslink Magnetic IP/Co-IP Kit (ThermoFisher Scientific)
following the manual’s instructions. Briefly, gastrocnemius muscles from mdx/
Actg1-TG mice were flash frozen and pulverized to a powder with a cooled mortar
and pestle. mdx/Actg1-TG muscles were used because γcyto-actin is expressed at
such low levels in WT mice that it cannot be detected with typical western blotting.
Samples were then solubilized with the kit’s IP Lysis Buffer (25 mM Tris pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% NP-40, and 5% glycerol) supplemented with
protease inhibitors (100 nM aprotinin, 1 mM benzamidine, 10 µM E-64, 10 µM
leupeptin, 1 mM pepstatin A, 1 mM phenylmethanesulfonylfluoride, 1 µM calpain
inhibitor I, and 1 µM calpeptin) by incubating for 30 min at 4 °C with end-over-end
rotation. Lysates were then cleared by centrifugation at 20,817 × g for 10 min at 4 °
C and protein concentrations were determined using the Pierce BCA Protein Assay
Kit (ThermoFisher Scientific). Samples were diluted to 0.5 mg/mL in 1 mL of IP
Lysis Buffer. During the protein sample preparation, 10 µg PrxII antibody (Sigma)
was coupled to Protein A/G magnetic beads and crosslinked using DSS (dis-
uccinimidyl suberate). Diluted protein was then incubated with the crosslinked
magnetic beads for 1 h at RT. Beads were washed thoroughly before the sample was
eluted with low pH Elution Buffer. Load, Void, Wash, and Elute fractions collected
during the immunoprecipitation were subjected to SDS-PAGE, transferred to
PVDF membranes, blocked with 5% milk in PBS, and probed with PrxII (Sigma)
and γcyto-actin (clone 2–4) primary antibodies overnight at 4 °C. Membranes were
incubated with DyLight secondary antibodies before being scanned on the Licor
Odyssey imaging system.
Cloning and generation of transgenic mice. Human peroxiredoxin-2 plasmid
cDNA was purchased from DNASU Plasmid Repository (Cat #HsCD00076134),
PCR amplified, inserted into the Gateway entry vector pENTR/D-TOPO (Invi-
trogen), and sequence verified. All PCRs were performed using PfuUltra Fusion HS
DNA Polymerase (Agilent Technologies). To make recombinant FLAG-PrxII
protein, pENTR/D-TOPO-PRDX2 was N-terminally FLAG-tagged (pENTR/D-
TOPO-N-FLAG-PRDX2) via PCR using primers that amplified the entire plasmid
with FLAG sequence overhangs. The linear PCR product was circularized via the
addition of T4 polynucleotide kinase and T4 DNA ligase (New England Biolabs)
and sequence verified. Once verified, the entry vector was recombined into the
Gateway insect cell destination vector pDEST8 (pDEST8-N-FLAG-PRDX2) using
LR Clonase II (Invitrogen) and subsequently expressed in Sf9 insect cells using the
Bac-to-Bac system (Invitrogen; see Protein expression and purification). To gen-
erate the PrxII-TG transgene, pENTR/D-TOPO-PRDX2 was recombined into a
pDEST8 destination vector already containing the HSA promoter followed by the
VP1 intron and tandem SV40 polyadenylation sequences (pDEST8-HSA-VP1-
SV40-SV40). The PrxII cDNA was inserted in-frame between the VP1 intron and
the first SV40 polyadenylation sequence (pDEST8-HSA-VP1-PRDX2-SV40-SV40).
The construct was transformed into DH5α bacteria cells and extracted using the
Wizard Plus SV Minipreps DNA Purification System (Promega). The DNA frag-
ment from the HSA promoter through the polyadenylation sequence was restric-
tion digested to linearize the transgene, gel purified via the QIAEX II Gel
Extraction Kit (Qiagen), and sent to the Murine Genetics Core at The Scripps
Research Institute for pronuclear microinjection into fertilized C57BL/6 zygotes,
which were then implanted into pseudo-pregnant female mice.
We obtained Fascin-1 cDNA (FSCN1) as a kind gift from Dr. Steven Almo of
the Albert Einstein College of Medicine. FSCN1 was PCR amplified, inserted into
the Gateway entry vector pENTR/D-TOPO (Invitrogen), and sequence verified. To
make recombinant FLAG-Fascin-1 protein, pENTR/D-TOPO-FSCN1 was N-
terminally FLAG-tagged (pENTR/D-TOPO-N-FLAG-FSCN1) via PCR using
primers that amplified the entire plasmid with FLAG sequence overhangs. The
linear PCR product was circularized via the addition of T4 polynucleotide kinase
and T4 DNA ligase (New England Biolabs) and sequence verified. Once verified,
the entry vector was recombined into the Gateway insect cell destination vector
pDEST8 (pDEST8-N-FLAG-FSCN1) using LR Clonase II (Invitrogen) and
subsequently expressed in Sf9 insect cells using the Bac-to-Bac system (Invitrogen;
see Methods - Protein expression and purification).
To generate C272A-TG and Actb-TG transgenes, both the pDEST8-HSA-VP1-
C272A-SV40-SV40 (C272A-TG) and pDEST8-HSA-VP1-ACTB-SV40-SV40
(Actb-TG) constructs were cloned based on the original pDEST8-HSA-VP1-
ACTG1-SV40-SV40 (Actg1-TG) construct previously described34. The C272A-TG
construct was generated via site-directed mutagenesis using the QuikChange II XL
kit (Agilent Technologies, Cat. no. 200521) according to the manufacture protocols
and sequence verified. Primers were designed to allow a two-nucleotide change
within the codon normally encoding Cysteine to then encode for Alanine at
position 272 (TGT to GCT). For Actb-TG, only the ACTG1 nucleotides that coded
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for the 4 γcyto-actin-specific amino acids (Glu2, Glu3, Glu4, and Ile10) were altered
to instead code for the 4 βcyto-actin-specific amino acids (Asp2, Asp3, Asp4, and
Val10) by editing the wobble base in each codon within the construct. This ensures
any differences described between transgenic mice are only due to the altered
amino acids, and not plasmid differences. The Actb-TG construct was generated
via PCR using primers designed such that they amplified the Actg1-TG plasmid
with ACTB-specific overhangs. The linear PCR product was circularized via the
addition of T4 polynucleotide kinase and T4 DNA ligase (New England Biolabs)
and sequence verified. Both constructs were transformed into DH5α bacteria cells
and extracted using the Wizard Plus SV Minipreps DNA Purification System
(Promega). The DNA fragment from the HSA promoter through the
polyadenylation sequence was restriction digested to linearize the transgene, gel
purified via the QIAEX II Gel Extraction Kit (Qiagen), and sent to the Murine
Genetics Core at The Scripps Research Institute for pronuclear microinjection into
fertilized C57BL/6 zygotes, which were then implanted into pseudo-pregnant
female mice.
Resultant PrxII-TG, C272A-TG, and Actb-TG transgenic founder mice were
identified by PCR using HSA-specific primers (Supplementary Table 2) and
crossed with C57BL/10 mice to check for transgene transmission. Transgenic PrxII
(PrxII-TG), γcyto-actin (C272A-TG), and βcyto-actin (Actb-TG) protein expression
was assessed in several different muscles from each transgenic line crossed onto the
mdx (C57BL/10ScSn-Dmdmdx/J) background using quantitative western blotting.
All mdx-transgenic mice used in this study were compared with non-transgenic
littermate mdx mice as controls.
Stretch-induced ROS measurements. Flexor digitorum brevus (FDB) muscles
were surgically isolated and incubated in Dulbecco's modified Eagle's medium
(DMEM; ThermoFisher Scientific) containing 0.1% penicillin–streptomycin
(ThermoFisher Scientific) and 0.4% Collagenase A (Sigma-Aldrich) at 37 °C for 2 h.
Single FDB fibers were isolated by gentle trituration in DMEM containing 0.1%
penicillin–streptomycin and 10% fetal bovine serum (ThermoFisher Scientific) and
incubated at 37 °C, 5% CO2 until used, typically 16–20 h later. Isolated FDB fibers
were washed three times with HEPES solution (120 mM NaCl, 4.7 mM KCl, 1.8
mM CaCl2, 600 µM MgSO4, 1.6 mM NaHCO3, 130 µM NaH2PO4, 7.8 mM Glu-
cose, and 20 mM HEPES) and loaded with 15 µM DCFH-DA (Invitrogen) for 25
min at RT in the dark. The fibers were then washed three times with HEPES
solution containing either dimethyl sulfoxide (DMSO; 0.1%) or gp91ds-tat (10 µM)
and the DCFH-DA dye was allowed to de-esterify for 15 min at RT in the dark. The
ends of each fiber were attached to a micro-glass pipet coated with a biological
adhesive (ECM Gel from Engelbreth-Holm-Swarm murine sarcoma, Sigma-
Aldrich) and connected to micro-manipulators (Sutter Instruments). DCF Fluor-
escence (Ex: 480 nm, Em: 535/40 nm) and sarcomere length were acquired using an
IonOptix system (Westwood, MA) atop a Motic AE31 microscope equipped with a
40× objective (Olympus UAP040X3/340). Each fiber was cyclically stretched to
110% of resting sarcomeric length (2–2.2 µm) at 10 µm/s for 15 min. The rate of
DCF fluorescence was reported during the last 2.5 min of stretch.
Evans blue dye assay. EBD was diluted in PBS to a final concentration of 5 mg/
mL and was filter-sterilized with a 0.2 µm filter. EBD was administered by intra-
peritoneal injection (100 µL of diluted EBD per 10 g body weight) 24 h before the
mice were subjected to eccentric contractions performed in vivo as previously
described84. Briefly, the left hind limb was depilated and aseptically prepared and
the foot was placed in a foot plate attached to a servomotor (Model 300B‐LR;
Aurora Scientific, Aurora, Ontario, Canada) and Pt–Ir electrode wires (Model E2‐
12; Grass Technologies, West Warwick, RI, USA) were inserted percutaneously on
either side of the peroneal nerve. Contractions were induced via stimulation of the
peroneal nerve at a frequency of 150 Hz by a stimulator and stimulus isolation unit
(Models S48 and SIU5, respectively; Grass Technologies). Anterior crural muscles
were injured by performing 70 electrically stimulated eccentric contractions (each
contraction separated by 10 s), during which the foot was passively rotated from 0°
to 19° dorsiflexion followed by 38° of plantarflexion at 2000°/s using the optimized
voltage. Both the TA subjected to ECC and the contralateral TA (control) of each
mouse were dissected and cryopreserved in melting isopentane before obtaining 10
µm cryosections at the mid-belly of each muscle. Sections were fixed in −20 °C
acetone for 5 min, washed in PBS, blocked for 30 min at room temperature with 5%
BSA/PBS, and counterstained with laminin (1:500; Sigma-Aldrich L9393) for 2 h at
RT. Sections were then washed in PBS and incubated with anti-Rabbit Alexa Flour
488 (1:500; ThermoFisher Scientific) for 1 h at RT. Sections were washed a final
time in PBS and mounted in ProLong Golf Antifade with DAPI (ThermoFisher
Scientific). Images were acquired on a Leica DM5500 B microscope equipped with
a Leica HC PLAN APO 10× objective and stitched together with LASX software
(Leica) to allow visualization of the entire TA. MyoVision software (https://www.
uky.edu/chs/muscle/myovision) was used to determine the percentage of EBD-
positive myofibers in whole-TA images85.
Statistical analysis. All statistics were calculated using GraphPad Prism software.
All data are presented as mean ± SEM in force loss graphs, dot plots, and bar
graphs. In force loss graphs, two-way ANOVA with Bonferroni post hoc test
analyses were performed. For dot plots and bar graphs, one-way ANOVA with
Tukey's post hoc test analyses were performed. For applicable experiments, the
exact value of n (defined by number of animals) and the definition of significance
can be found in the figure legend.
Data availability
The data that support the findings of this study are available from the corre-
sponding author upon reasonable request. The mass spectrometry proteomics data
have been deposited to the ProteomeXchange Consortium via the PRIDE partner
repository with the dataset identifier PXD009680. A reporting summary for this
article is available as a Supplementary Information file.
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